Skip to content

Global Performance Evaluation of the AMS CONTINUUM™ Device

Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01083199
Enrollment
10
Registered
2010-03-09
Start date
2007-10-31
Completion date
2010-11-30
Last updated
2016-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Prostate Cancer, Radical Prostatectomy, Vesico-Urethral Anastomosis

Brief summary

1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure. 2. To assess clinical outcomes of the Device in facilitating the vesico-urethral anastomosis following a radical prostatectomy.

Detailed description

Radical prostatectomy (RP) is the most utilized surgical treatment option for localized prostate cancer due to the multi-focal nature of the disease. RP is most suitable for otherwise healthy men whose cancer is limited to a small area. The RP procedure involves removing the prostate gland, seminal vesicles and nearby lymph nodes. One of the most technically challenging and critical aspects in all of these surgical approaches is reconstruction of the interrupted urinary tract by hand sewing the vesico-urethral anastomosis. This is where the bladder neck is sewn to the urethra after the prostate has been removed. CONTINUUM™ (study Device) is to be used as part of the RP procedure by facilitating the approximation of the bladder neck and urethral stump. The Device brings together and holds the tissue in place until adequate natural healing of the vesico-urethral anastomosis occurs thereby minimizing extravasation. The Device also provides a conduit for drainage of urine from the bladder out the urethra during tissue healing. The concept of the CONTINUUM™ device and the feasibility of its operation have been successfully tested in animal and human studies. Pilot clinical studies in the United States (G060095) found that the majority of subjects who received and were discharged with the Device demonstrated a water-tight vesico-urethral anastomosis at the first Device removal visit. Additionally, no unanticipated adverse device effects (UADEs) were reported. The focus of the proposed study is to further verify the performance of the Device in global research centers.

Interventions

Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.

Sponsors

American Medical Systems
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All males ≥ 40 years old who are indicated for a radical prostatectomy will be eligible to participate in the study

Exclusion criteria

* If contraindicated for surgery * Inability to understand the study or a history of non-compliance with medical advice * Unwilling or unable to sign an Informed Consent Form (ICF) * A history of: 1. Recurrent urinary tract infections (UTI) 2. Recurrent stricture disease * Neurological disease with a history of bladder dysfunction (e.g., Parkinson's disease) * Uncontrolled insulin-dependent diabetes * Chemotherapy within the past 6 months * Non-topical steroid use within the past 6 months * Allergy to nitinol, nickel, titanium or silicone

Design outcomes

Primary

MeasureTime frameDescription
Successful Device PlacementDuring Radical ProstatectomySuccessful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.
Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement7-21 days post-Device placementDevice removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window. The following defines the timeframe of each removal attempt: * 7-day window (7-10 days post-implant) * 14-day window (13-15 days post-implant) * 21-day window (19-21 days post-implant)

Secondary

MeasureTime frame
Intraoperative/Postoperative ParametersAt Device placement
Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits7 and 14 days post-Device placement
Incontinence Rate and I-QOL ScoreBaseline, 6-week, 6 and 12-month evaluations
Bladder Neck Contracture (BNC) RateSubjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal

Countries

Greece, Spain

Participant flow

Participants by arm

ArmCount
AMS CONTINUUM™ Device10
Total10

Baseline characteristics

CharacteristicAMS CONTINUUM™ Device
Age, Continuous64.7 Years
STANDARD_DEVIATION 7.9
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
6 / 10
serious
Total, serious adverse events
6 / 10

Outcome results

Primary

Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement

Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window. The following defines the timeframe of each removal attempt: * 7-day window (7-10 days post-implant) * 14-day window (13-15 days post-implant) * 21-day window (19-21 days post-implant)

Time frame: 7-21 days post-Device placement

ArmMeasureValue (NUMBER)
Continuum DeviceFunctionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement10 participants with device removal by 21d
Primary

Successful Device Placement

Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.

Time frame: During Radical Prostatectomy

ArmMeasureValue (NUMBER)
Continuum DeviceSuccessful Device Placement10 participants
Secondary

Bladder Neck Contracture (BNC) Rate

Time frame: Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal

Secondary

Incontinence Rate and I-QOL Score

Time frame: Baseline, 6-week, 6 and 12-month evaluations

Secondary

Intraoperative/Postoperative Parameters

Time frame: At Device placement

Secondary

Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits

Time frame: 7 and 14 days post-Device placement

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026